Literature DB >> 2334412

Enhanced binding activity of an apolipoprotein E mutant, APO E5, to LDL receptors on human fibroblasts.

L M Dong1, T Yamamura, A Yamamoto.   

Abstract

We have previously demonstrated an apolipoprotein E (apo E) mutant, apo E5, associated with hyperlipidemia and atherosclerotic vascular diseases. To investigate the possible mechanism of apo E5 involvement in the development of hyperlipidemia, we have isolated the apo E isoprotein and determined its binding activity to LDL (low density lipoprotein) receptors. It was shown that the apo E5 isoprotein was two times more active for binding to LDL receptors than apo E3. The concentration of apo E, at which 50% of 125I-labeled LDL bound to the receptor was displaced, was 29 ng/ml for apo E5 and 63 ng/ml for apo E3. This result suggests that the high affinity of apo E5 to LDL receptors results in a high uptake of apo E5-containing lipoproteins by the liver and leads to a down-regulation of LDL receptors in the liver. We can postulate that individuals with apo E5 are susceptible to hypercholesterolemia and in consequence to atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2334412     DOI: 10.1016/0006-291x(90)92336-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I.

Authors:  Satoshi Takasaki; Akira Matsunaga; Kensuke Joh; Takao Saito
Journal:  CEN Case Rep       Date:  2018-01-22

2.  Focal segmental glomerulosclerosis with heterozygous apolipoprotein E5 (Glu3Lys).

Authors:  Masaru Sasaki; Tetsuhiko Yasuno; Kenji Ito; Akira Matsunaga; Satoshi Hisano; Yasuhiro Abe; Katsuhisa Miyake; Kosuke Masutani; Hitoshi Nakashima; Takao Saito
Journal:  CEN Case Rep       Date:  2018-05-08

3.  A Case of Lipoprotein Glomerulopathy with apoE Chicago and apoE (Glu3Lys) Treated with Fenofibrate.

Authors:  Hitoshi Kodera; Yasuhide Mizutani; Satoshi Sugiyama; Toshio Miyata; Takashi Ehara; Akira Matsunaga; Takao Saito
Journal:  Case Rep Nephrol Dial       Date:  2017-07-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.